2018 Center for Biologics Evaluation and Research Science Symposium [USFDA-CBER]
The Food and Drug Administration (FDA) is announcing the following public symposium entitled ‘‘2018 Center for Biologics Evaluation and Research Science Symposium.’’ The purpose of the public symposium is to discuss scientific topics related to the regulation of biologics and highlight science conducted at the Center for Biologics Evaluation and Research (CBER) by showcasing how scientific research informs regulatory decision making and to provide a forum for developing collaborations within FDA and with external organizations. The symposium will include presentations by experts from academic institutions, government agencies, and research institutions.
The public symposium will be held on June 25 and 26, 2018, from 9 a.m. to 3 p.m.
TOPICS FOR DISCUSSION
The public symposium will include presentations on the following topics:
(1) Emerging and re-emerging diseases;
(2) diverse types of data in regulatory decision making;
(3) immune response to vaccination;
(5) new technologies for research and treatments; (6) the role of the microbiome in human disease; and
(7) regenerative medicine.
Participating in the Public Symposium could be in person or by webast.
Registration is free and based on space availability, with priority given to early registrants. Persons interested in attending this public symposium (either in person or by webcast) (see Streaming Webcast of the Public Symposium) must register online by June 18, 2018, midnight Eastern Time. Early registration is recommended because seating is limited. There will be no onsite registration; therefore, FDA may limit the number of participants from each organization. Registrants will receive confirmation when they have been accepted.
For more information go to https://www.gpo.gov/fdsys/pkg/FR-2018-03-22/pdf/2018-05805.pdf